Nous avons pris note de l’alerte lancée par la FDA (USA) concernant le décès d'un…
MaaT Pharmajuin 14, 2019
“Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute…
MaaT Pharmamai 21, 2019
- First patents to cover the fundamental processes for accessing the human gut microbiome as…
MaaT Pharmamai 21, 2019
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute…
MaaT Pharmaavril 9, 2019
Le comité de surveillance et de suivi (DSMB) recommande de poursuivre l’étude HERACLES sans modifications.…
MaaT Pharmafévrier 5, 2019
Data show achievement of primary endpoint, demonstration of functional microbiota restoration, inflammation reduction and positive…
MaaT Pharmadécembre 2, 2018
Lyon, France, November 2, 2018 – MaaT Pharma announced today that the company will present…
MaaT Pharmanovembre 6, 2018
Results from in silico analysis using MaaT Pharma’s data analysis platform, GutPrint, demonstrate therapeutic rationale…
MaaT Pharmaseptembre 18, 2018
MaaT Pharma receives world-wide exclusive license to technology co-developed with hematology and gastroenterology departments of…
MaaT Pharmajuin 21, 2018
